Main Article Content
Background. Postmenopausal osteoporosis is an issue of great concern as it results in an elevated risk of fractures with a further negative impact on the elderly women’s health. The osteoporosis may be diagnosed based on the low-energy fractures occurring with no major trauma, or based on the low bone mineral density (BMD) measured by dual-energy X-ray absorptiometry (DXA). The purpose of study is to examine 25(ОН)D level, 10-year probability of major osteoporotic fractures, bone mineral density and quality, fat and lean mass and to analyze their associations in the pre- and postmenopausal women. Materials and methods. Three hundred and two women aged 45–80 years (mean age — 61.3 ± 7.7 years) were examined and divided into 6 groups according to the pre- and postmenopausal period duration: group I — premenopausal women (n = 36; mean age — 50.1 ± 3.4 years); groups II–VI — postmenopausal women (n = 266; mean age — 62.8 ± 6.8 years). All the examined patients were subjected to bone mineral density measurement by the DXA on Prodigy system (GE Medical Systems, model 8743, 2005) according to the standard protocol. BMD and T-score of the lumbar spine, femoral neck and total skeleton were evaluated. Trabecular bone score of lumbar spine was measured by TBS iNsight (Med-Imaps, Pessac, France). Total 25(ОН)D was assessed by electrochemoluminescent method using Еlecsys 2010 analyzer (Roche Diagnostics, Germany) and Cobas test systems. The 10-year probability of major osteoporotic fractures and hip fractures was calculated by the Ukrainian FRAX model without DXA results considered. Total body fat and lean mass was assayed by the dual-energy X-ray absorptiometry (Prodigy, GE). Results. We found a significant association between the pre- and postmenopausal period duration and bone density and quality variables (trabecular bone score (F = 6.85; p < 0.001), BMD of lumbar spine (F = 5.53; p < 0.001), BMD of femoral neck (F = 10.25; p < 0.001), BMD of total skeleton (F = 12.28; p < 0.001)). Among 266 postmenopausal women examined, 90 (33.8 %) had osteoporosis diagnosed at the lumbar spine, 108 (40.6 %) had osteopenia, 68 (25.6 %) — normal bones; 47 (17.7 %) people had osteoporosis diagnosed at the femoral neck, 187 (70.3 %) women had osteopenia, 32 (12.0 %) had normal bones. The 10-year probability of major osteoporotic fractures significantly increased compared with a premenopausal age during the following postmenopausal stages: 5–9 years — 3.58 ± 1.97 and 6.72 ± 3.23, p < 0.0001; 10–14 years — 3.58 ± 1.97 and 6.90 ± 2.78, p < 0.0001; 15–19 years — 3.58 ± 1.97 and 7.19 ± 3.23, p < 0.0001; 20–24 years — 3.58 ± 1.97 and 8.03 ± 2.45, p < 0.0001. Vitamin D deficiency was observed in 39.7 % (n = 120) of cases, insufficiency — in 30.4 % (n = 92), 29.9 % of women had normal bones (n = 90). We didn’t register any seasonal or monthly impact as far as 25(ОН)D is concerned (F = 0.51; p = 0.89). The 25(ОН)D level had a negative correlation with body weight, body mass index, fat mass indices, and positive — with a 10-year probability of major osteoporotic fractures. Conclusions. The obtained results indicate a significant negative impact of pre- and postmenopause duration on bone mineral density and quality variability, and a positive one — on the 10-year probability of major osteoporotic fractures and hip fractures. For the postmenopausal women, obesity is a protective factor against bone loss and developing osteoporosis, which is likely due to the elevated adipocyte rate. According to the regression analysis, there is a confirmed negative correlation between body weight, body mass index, total fat mass and 25(ОН)D concentration in the blood serum. The above-mentioned fact requires elaboration of an adequate therapeutic approach when the vitamin D deficiency is associated with obesity.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
Dorodneva EF, Isakova DN, Efanov AY. Role of endothelin-1 in the development of cardiovascular disease in patients with diabetes. Medicinskaia nauka i obrazovanie Urala. 2013;(1):172-176. (in Russian).
Tang ST, Su H, Zhang Q, et al. Sitagliptin inhibits endothelin-1 expression in the aortic endothelium of rats with streptozotocin-induced diabetes by suppressing the nuclear factor-κB/IκBα system through the activation of AMP-activated protein kinase. Int J Mol Med. 2016;37(6):1558‐1566. doi:10.3892/ijmm.2016.2578.
Maamoun H, Benameur T, Pintus G, Munusamy S, Agouni A. Crosstalk Between Oxidative Stress and Endoplasmic Reticulum (ER) Stress in Endothelial Dysfunction and Aberrant Angiogenesis Associated With Diabetes: A Focus on the Protective Roles of Heme Oxygenase (HO)-1. Front Physiol. 2019;10:70. doi:10.3389/fphys.2019.00070.
Tronko ND, Pushkarev VM, Sokolova LC, Pushkarev VV, Kovzun EI. Molekuliarnye mekhanizmy patogeneza sakharnogo diabeta i ego oslozhnenii [Molecular mechanisms of the pathogenesis of diabetes mellitus and its complications]. Kyiv: Medknyga; 2018. 264 p. (in Russian).
Young A, Wu W, Sun W, et al. Flow activation of AMP-activated protein kinase in vascular endothelium leads to Krüppel-like factor 2 expression. Arterioscler Thromb Vasc Biol. 2009;29(11):1902‐1908. doi:10.1161/ATVBAHA.109.193540.
Spinella F, Caprara V, Cianfrocca R, et al. The interplay between hypoxia, endothelial and melanoma cells regulates vascularization and cell motility through endothelin-1 and vascular endothelial growth factor. Carcinogenesis. 2014;35(4):840‐848. doi:10.1093/carcin/bgu018.
Chen S, Feng B, George B, Chakrabarti R, Chen M, Chakrabarti S. Transcriptional coactivator p300 regulates glucose-induced gene expression in endothelial cells. Am J Physiol Endocrinol Metab. 2010;298(1):E127‐E137. doi:10.1152/ajpendo.00432.2009.
Zhan S, Rockey DC. Tumor necrosis factor α stimulates endothelin-1 synthesis in rat hepatic stellate cells in hepatic wound healing through a novel IKK/JNK pathway. Exp Cell Res. 2011;317(7):1040‐1048. doi:10.1016/j.yexcr.2010.12.026.
Boesen EI, Sasser JM, Saleh MA, et al. Interleukin-1beta, but not interleukin-6, enhances renal and systemic endothelin production in vivo. Am J Physiol Renal Physiol. 2008;295(2):F446‐F453. doi:10.1152/ajprenal.00095.2008.
El-Mesallamy H, Suwailem S, Hamdy N. Evaluation of C-reactive protein, endothelin-1, adhesion molecule(s), and lipids as inflammatory markers in type 2 diabetes mellitus patients. Mediators Inflamm. 2007;2007:73635. doi:10.1155/2007/73635.
Vatseba TS, Sokolova LK, Pushkarev VM. The effect of obesity on the formation of cancer risk in patients with type 2 diabetes mellitus (literature review). Mìžnarodnij endokrinologìčnij žurnal. 2020;16(2):161-167. doi:10.22141/2224-0722.214.171.1240.201303. (in Ukrainian).